Skip to main content

Table 1 Baseline characteristics before and after propensity-score matching

From: Catheter ablation or surgical therapy in moderate-severe tricuspid regurgitation caused by long-standing persistent atrial fibrillation. Propensity score analysis

 

Pre-matching

Post-matching

Catheter n = 279

Surgical n = 114

SMD

Catheter n = 111

Surgical n = 111

SMD

Age, yrs

69.1 ± 4.2

68.3 ± 4.8

0.095

69.0 ± 4.7

68.8 ± 4.5

0.15

Male

153 (54.8)

60 (52.6)

0.209

60 (54.1)

58 (52.3)

−0.177

BMI, kg/m2

22.8 ± 2.3

22.7 ± 2.7

0.097

22.7 ± 2.5

22.7 ± 2.5

0.074

NYHA Class

2.3 ± 0.4

2.5 ± 0.6

0.027

2.3 ± 0.5

2.3 ± 0.5

0.026

Smoking

71 (25.4)

30 (26.4)

−0.158

28 (25.2)

29 (26.1)

−0.127

Diabetes

29 (10.4)

13 (11.4)

−0.202

12 (10.8)

12 (10.8)

0.049

Hypertension

61 (21.9)

27 (23.7)

−0.148

25 (22.5)

26 (23.4)

−0.196

Stroke

34 (12.2)

17 (14.9)

0.016

15 (13.5)

16 (14.4)

0

CAD

31 (11.1)

15 (13.2)

0.003

14 (12.6)

14 (12.6)

0.081

COPD

12 (4.3)

6 (5.3)

0.016

5 (4.5)

5 (4.5)

−0.203

CHADS2 Score

0.68 ± 1.32

0.70 ± 1.82

0.058

0.69 ± 1.19

0.70 ± 1.23

0.076

Euro SCORE

0.75 ± 1.02

0.79 ± 1.10

−0.175

0.76 ± 1.09

0.78 ± 1.12

−0.274

AF duration, years

2.5 ± 1.1

3.3 ± 1.6

0.169

2.5 ± 1.2

2.6 ± 1.3

0

Medication

 ACE I

51 (18.2)

22 (19.3)

0.009

21 (18.9)

21 (18.9)

0.155

 ARB

27 (9.7)

13 (11.4)

−0.011

11 (10.0)

12 (10.8)

0.176

 CCB

20 (7.1)

11 (9.6)

−0.007

9 (8.1)

10 (9.0)

−0.137

 Beta-blocker

52 (18.6)

14 (12.3)

0.136

15 (13.5)

14 (12.6)

−0.127

 Digitalis

78 (28.0)

22 (19.3)

0.144

24 (21.6)

22 (19.8)

−0.156

 Diuretics

83 (29.7)

24 (21.1)

0.113

26 (23.4)

24 (21.6)

−0.121

 Amiodarone

100 (35.8)

30 (26.3)

−0.421

32 (28.8)

30 (27.0)

−0.17

LVESD, mm

36.1 ± 10.1

37.5 ± 11.6

0.013

36.9 ± 11.5

37.1 ± 10.8

0.105

LVEDD, mm

52.1 ± 5.8

53.7 ± 6.8

−0.163

52.8 ± 6.1

53.0 ± 6.3

0.161

sPAP, mmHg

39.1 ± 9.2

40.7 ± 6.2

−0.184

39.8 ± 8.9

40.0 ± 7.1

0.125

LAD, mm

52.1 ± 11.7

53.6 ± 10.8

−0.011

52.6 ± 10.3

52.9 ± 10.9

−0.055

LVEF, %

60.1 ± 8.2

58.6 ± 9.2

−0.127

59.6 ± 8.9

59.1 ± 9.0

0.071

RAA, mm2

19.7 ± 5.1

20.9 ± 3.5

−0.164

20.0 ± 4.9

20.1 ± 4.9

0.219

RVSI

2.0 ± 0.2

2.0 ± 0.5

−0.162

2.0 ± 0.3

2.0 ± 0.3

0.165

RVFAC, %

43.1 ± 4.8

42.2 ± 6.7

−0.243

42.7 ± 4.3

42.4 ± 5.1

−0.042

Tethering height, mm

7.1 ± 3.6

8.9 ± 3.9

−0.294

7.9 ± 3.4

8.2 ± 3.7

0.017

Tethering area, cm2

2.8 ± 0.8

3.7 ± 0.7

0.217

2.9 ± 0.9

3.2 ± 0.5

0

TR EROA, cm2

0.8 ± 0.4

0.9 ± 0.8

−0.127

0.8 ± 0.5

0.8 ± 0.7

−0.157

TR VC, cm

1.0 ± 0.4

1.0 ± 0.7

−0.133

1.0 ± 0.2

1.0 ± 0.3

0.075

TR grade

3.4 ± 0.7

3.7 ± 0.5

0.022

3.5 ± 0.5

3.6 ± 0.2

−0.095

TAD, cm

36.5 ± 4.1

39.1 ± 5.2

0.003

37.9 ± 4.9

38.8 ± 5.0

0.081

  1. ACEI Angiotensin-converting enzyme inhibitor, AF Atrial fibrillation, ARB Angiotensin receptor blocker; BMI Body mass index, CAD Coronary artery disease, CCB Calcium channel blocker, COPD Chronic obstructive pulmonary disease, EROA Effective regurgitant orifice area, LAD Left atrial diameter, LVEF Left ventricle ejection fraction, LVEDD Left ventricle end-diastolic dimension, LVESD Left ventricle end-systolic dimension, NYHA New York Heart Association, RAA Right atrial area, RVFAC Right ventricle fractional area change, RVSI Right ventricle sphericity index, SMD Standard mean diference, sPAP Pulmonary artery systolic pressure, TAD Tricuspid annulus diameter, TR Tricuspid regurgitation, VC Vena contracta